Metsera (NASDAQ:MTSR) Shares Up 4.5% - Should You Buy?

Metsera, Inc. (NASDAQ:MTSR - Get Free Report) was up 4.5% during trading on Thursday . The stock traded as high as $34.88 and last traded at $34.56. Approximately 280,593 shares changed hands during mid-day trading, a decline of 69% from the average daily volume of 908,462 shares. The stock had previously closed at $33.06.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the company. Guggenheim upped their price objective on Metsera from $56.00 to $62.00 and gave the stock a "buy" rating in a research note on Tuesday, June 10th. Cantor Fitzgerald assumed coverage on Metsera in a report on Tuesday, February 25th. They set an "overweight" rating on the stock. Bank of America initiated coverage on Metsera in a research note on Tuesday, February 25th. They issued a "buy" rating and a $38.00 price objective on the stock. Finally, Evercore ISI initiated coverage on Metsera in a research report on Tuesday, February 25th. They issued an "outperform" rating for the company.

Metsera Stock Down 15.0%

The company's 50 day simple moving average is $24.39.

Metsera (NASDAQ:MTSR - Get Free Report) last posted its quarterly earnings data on Monday, May 12th. The company reported ($1.03) earnings per share (EPS) for the quarter.

Institutional Investors Weigh In On Metsera

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Alphabet Inc. bought a new position in Metsera during the 1st quarter valued at approximately $135,059,000. T. Rowe Price Investment Management Inc. bought a new position in Metsera during the 1st quarter valued at approximately $78,748,000. Wellington Management Group LLP bought a new position in Metsera during the 1st quarter valued at approximately $65,382,000. Alpha Wave Global LP purchased a new stake in Metsera during the 1st quarter valued at $64,894,000. Finally, Price T Rowe Associates Inc. MD purchased a new stake in Metsera during the 1st quarter valued at $42,395,000.

Metsera Company Profile

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.